Skip to main content

Jeffrey Conn

Study explores potential new class of antidepressants

Nov. 21, 2019—Researchers at VUMC have taken a major step that could ultimately facilitate development of a new class of antidepressants which may relieve symptoms more rapidly and effectively and with fewer side effects than current medications.

Read more


Yohn named Postdoc of the Year at annual symposium; Sappington named Mentor of the Year

Apr. 22, 2019—Postdoctoral scholars Samantha Yohn and Anneke Sanders and ophthalmology professor Rebecca Sappington were honored by the Graduate School at the 13th Annual Vanderbilt Postdoctoral Association Symposium on April 9.

Read more


Ancora announces major funding awards to support Vanderbilt drug discovery research

Nov. 26, 2018—Ancora Innovation, LLC, the new collaboration between Vanderbilt and Deerfield Management established earlier this year, has completed its inaugural proposal review process and announced two projects selected for funding.

Read more


Investigators eye new target for treating movement disorders

Jan. 18, 2018—Blocking a nerve-cell receptor in part of the brain that coordinates movement could improve the treatment of Parkinson’s disease, dyskinesia and other movement disorders, researchers at Vanderbilt University have reported.

Read more


Vanderbilt signs licensing, research agreements to develop new approach to schizophrenia treatment

Jan. 8, 2018—Under the terms of the licensing agreement, Lundbeck has exclusively licensed rights to compounds developed at Vanderbilt that act on a receptor in the brain that has been implicated in schizophrenia.

Read more


Vanderbilt researchers’ papers among those most cited

Dec. 7, 2017—Eight current faculty members at Vanderbilt have made this year’s list of scientists whose papers have been cited most frequently by other researchers.

Read more


Award honors Conn’s mental health research contributions

Oct. 12, 2017—P. Jeffrey Conn, Ph.D., founding director of the Vanderbilt Center for Neuroscience Drug Discovery, has won a 2017 Research & Hope Award from the Pharmaceutical Research and Manufacturers of America (PhRMA) for outstanding research in the area of mental health.

Read more


Vanderbilt begins Phase 1 trials of new Alzheimer’s drug

Aug. 7, 2017—Developed at Vanderbilt, VU319 is designed to precisely target a specific neuron receptor associated with cognitive function while avoiding potentially dangerous side effects.

Read more


Researchers eye potential schizophrenia ‘switch’

Sep. 15, 2016—Researchers at Vanderbilt University Medical Center have discovered a key mechanism that explains how compounds they’re developing can suppress schizophrenia-like symptoms without side effects in mice.

Read more


Compound developed at VUMC may delay Huntington’s disease

Oct. 29, 2015—A compound developed by researchers at Vanderbilt University can improve early symptoms and delay progression of Huntington’s disease in a mouse model of the neurodegenerative disorder.

Read more


Five VUMC faculty members on list of most frequently cited researchers

Oct. 8, 2015—Five current faculty members at Vanderbilt University Medical Center have made this year’s list of scientists whose papers have been cited most frequently by others.

Read more


Findings reveal new target in quest to ease schizophrenia

May. 7, 2015—Vanderbilt University researchers have uncovered a surprising finding that could lead to the development of new, more effective therapies for schizophrenia, which affects more than 2 million Americans.

Read more


VIEW MORE EVENTS >